![](https://www.worldpharmatoday.com/images/nBanners/Docuvera-728x90.jpeg")
Drug Research
Allos recruits first patient in Phase 3 PTCL drug trial
Allos Therapeutics has recruited first patient in a Phase 3 multi-center, randomized, open-label (PDX-017) Phase 2 trial investigating Folotyn (pralatrexate injection) in patients with...
Drug Research
Abbott two new strengths of CPP drug gets FDA nod
Abbott has received the US Food and Drug Administration (FDA) approval for two new strengths of Lupron Depot-PED (leuprolide acetate for depot suspension) to...
Drug Research
AVI BioPharma starts patient dosing in DMG drug Phase 2 trial
AVI BioPharma has started patient dosing in a placebo-controlled Phase 2 trial to evaluate eteplirsen as a treatment for Duchenne muscular dystrophy (DMD).The study...
Drug Research
Biogen Idec, Abbott release Select Phase 2b RRMS drug trial results
Biogen Idec and Abbott have released top-line results from a double-blind, dose-ranging, randomized and placebo-controlled Select Phase 2b trial evaluating the experimental compound daclizumab...
Drug Research
Innovacyn introduces eye, ear formulations
Innovacyn, a provider of human and animal healthcare products, has added Vetericyn VF Ophthalmic Wash and Vetericyn VF Otic Rinse to its professional-strength animal...
Drug Research
Glenmark settles patent case with Daiichi, Genzyme
Glenmark Pharmaceuticals has settled patent litigation suit with Daiichi Sankyo and Genzyme in relation to its type-2 diabetes treatment Colesevelam Hydrochloride’s abbreviated new drug...
Drug Research
RxMD signs drug development agreement with GlycoRegImmune
RxMD has collaborated with GlycoRegImmune (GRI) to develop new treatments by using GRI's novel natural killer (NK) T cell targeted technologies for autoimmune, inflammatory...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read